Targeting Epilepsy Ictogenesis Process Through Pannexin-1 Modulation

Informations projet

PanThera

N° de convention de subvention: 101069281

DOI

10.3030/101069281

Projet clôturé

Date de signature de la CE 31 Mai 2022

Date de début 1 Octobre 2022

Date de fin 31 Mars 2024

Financé au titre de

• European Research Council (ERC)

Coût total

Aucune donnée

Contribution de l’UE

€ 150 000,00

Coordonné par

COLLEGE DE FRANCE
France

Periodic Reporting for period 1 - PanThera (Targeting Epilepsy Ictogenesis Process Through Pannexin-1 Modulation)

Période du rapport: 2022-10-01 au 2024-03-31

Résumé du contexte et des objectifs généraux du projet

Epilepsy, affecting about 1% of the population, comprises a group of neurological disorders characterized by the periodic occurrence of seizures, which disrupt normal brain function. Despite treatment with current antiepileptic drugs, one third of epileptic patients are pharmacoresistant and most patients suffer from side effects, making it crucial to develop novel therapies. Current drugs indeed target channels and receptors involved in normal brain function, not specific to the disease.
Our academic work has recently identified a novel and innovative target for epilepsy, which is active during the transition to epileptic seizures. This target could therefore allow to specifically counteract epileptic seizures without altering physiological cerebral processes. Our preclinical investigations have shown that a molecule acting on this target can counteract seizures both ex vivo in human postoperative epileptic tissues and in vivo in an animal model of recurrent focal epilepsy. These results led to a patent for the use of this molecule to treat epileptic conditions. Our project aimed at completing the pharmacological preclinical package of this molecule as an antiepileptic drug.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

To do so, we characterized its pharmacodynamic-pharmacokinetic activity, tested its dose effect in a model of focal epilepsy, as well as assessed its effect on another form on epilepsy.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

This study should contribute to bring to the market a new generation of antiepileptic drugs.